KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash & Current Investments: 2018-2025

Historic Cash & Current Investments for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $92.4 million.

  • Esperion Therapeutics' Cash & Current Investments fell 36.12% to $92.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $437.9 million, marking a year-over-year decrease of 31.88%. This contributed to the annual value of $144.8 million for FY2024, which is 76.01% up from last year.
  • Esperion Therapeutics' Cash & Current Investments amounted to $92.4 million in Q3 2025, which was up 7.42% from $86.1 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Cash & Current Investments ranged from a high of $259.3 million in Q4 2021 and a low of $82.2 million during Q4 2023.
  • For the 3-year period, Esperion Therapeutics' Cash & Current Investments averaged around $136.0 million, with its median value being $138.5 million (2023).
  • As far as peak fluctuations go, Esperion Therapeutics' Cash & Current Investments surged by 82.63% in 2022, and later plummeted by 54.54% in 2025.
  • Esperion Therapeutics' Cash & Current Investments (Quarterly) stood at $259.3 million in 2021, then plummeted by 35.66% to $166.9 million in 2022, then tumbled by 50.71% to $82.2 million in 2023, then surged by 76.01% to $144.8 million in 2024, then plummeted by 36.12% to $92.4 million in 2025.
  • Its Cash & Current Investments stands at $92.4 million for Q3 2025, versus $86.1 million for Q2 2025 and $114.6 million for Q1 2025.